Published in Law and Health Weekly, May 7th, 2005
The agreement, made under the Powered by Affymetrix program, gives bioMerieux non-exclusive rights to Affymetrix' patented arrays, instrumentation systems and future improvements to these key technologies. Financial terms of the agreement were not disclosed.
"Microarrays are on the path to becoming a clinical reality in oncology, helping clinicians to provide a more...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.